CurrentCignaPolicy N/A

Diuretics - Hydrochlorothiazide Step Therapy Policy

Defines step therapy requirements for coverage of hydrochlorothiazide products (generic tablets/capsules and Inzirqo suspension) under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyDiuretics - Hydrochlorothiazide Step Therapy Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionRequire trial of a generic hydrochlorothiazide tablet or capsule before approving Step 2 (Inzirqo suspension); approvals are provided for 1 year.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2step levels

1 yearapproval duration

InzirqoStep 2 product

generic HCTZStep 1 products

Coverage Criteria

Step 2 (Inzirqo) coverage criteria

Covered when ALL of the following are met

Top-level: Coverage of Step 2 Product (Inzirqo suspension) is allowed only when the step therapy criteria below are met; approvals are for 1 year.

Allow if any of the following are true

Trial of Step 1: Patient has tried one Step 1 product (generic hydrochlorothiazide tablets or capsules).
Document prior trial.
Swallowing difficulty: Patient cannot swallow or has difficulty swallowing tablets or capsules.
Acceptable to allow suspension formulation.

Policy Summary

PayerCigna

PolicyDiuretics - Hydrochlorothiazide Step Therapy Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionRequire trial of a generic hydrochlorothiazide tablet or capsule before approving Step 2 (Inzirqo suspension); approvals are provided for 1 year.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Step Therapy Requirements

Requirement	Details	Coverage status
Trial of Step 1 product
Patient has tried one generic hydrochlorothiazide tablet or capsule (Step 1).
Coverage allowed for Step 2 (Inzirqo suspension) after trial of one Step 1 product.
Swallowing difficulty exception
Patient cannot swallow or has difficulty swallowing tablets or capsules — Step 2 may be approved without a Step 1 trial.
Coverage allowed for Step 2 (Inzirqo suspension) when swallowing difficulty prevents use of tablets/capsules.
Dosing not achievable with tablets/capsules
Prescribed dose cannot be obtained with whole tablets or capsules of available hydrochlorothiazide strengths (e.g., 12.5 mg, 25 mg, 50 mg) — Step 2 may be approved.
Coverage allowed for Step 2 (Inzirqo suspension) when required dose cannot be achieved with available tablet/capsule strengths.

Provider Actions and Prior Authorization

Billing Rule

Billing and documentation expectations

Providers must submit prior authorization requests consistent with the member's applicable benefit plan terms and Cigna policy. Use the most appropriate billing and diagnosis codes for the service/date of submission; claims submitted without covered codes or with incomplete documentation may be denied. Supporting documentation should include clinical rationale, prior medication trials (including product name, dose, dates tried, and reason for failure or intolerance), and any swallowing/dosing limitations.

Use current procedure and diagnosis codes effective on date of service.
Include medication trial history: product name, dose, start/stop dates, and reason for discontinuation.
Attach documentation for dysphagia or inability to swallow tablets when applicable.

Step Therapy

Hydrochlorothiazide step therapy requirements

A trial of a Step 1 product (generic hydrochlorothiazide tablets or capsules) is required before approving the Step 2 product (Inzirqo suspension), unless an exception below is met. Approvals are issued for 1 year when criteria are satisfied.

Step 1: generic hydrochlorothiazide tablets or capsules.
Step 2: Inzirqo suspension.
If patient has tried one Step 1 product, approve Step 2.

Denial Risk

Denial trigger for unmet step therapy

Coverage for a Step 2 product may be denied at the point of service if the Step Therapy rule is not met. Exceptions that warrant approval include documented inability to swallow tablets or capsules, or when the prescribed dose cannot be achieved using whole tablets/capsules (e.g., required dose not available in 12.5 mg, 25 mg, or 50 mg strengths). All approvals are valid for 1 year.

Denial risk exists if required Step 1 trial is not documented.
Approve if patient cannot swallow or has difficulty swallowing tablets/capsules.
Approve if prescribed dose cannot be obtained with whole tablets or capsules of available strengths.

Definitions

Hydrochlorothiazide — Definition

Drug classThiazide diuretic

IndicationsTreatment of hypertension in adults and pediatric patients; treatment of edema associated with congestive heart failure, hepatic cirrhosis, and renal disease (including nephrotic syndrome)

Formulations referenced in policyTablets, capsules, suspension

Step therapy product definitions

Step 1 (preferred)Generic hydrochlorothiazide tablets or capsules

Step 2Inzirqo (hydrochlorothiazide suspension)

Approval durationApprovals are provided for 1 year

Policy stanceProgram encourages use of Step 1 before Step 2; exceptions specified in criteria

Background

Hydrochlorothiazide is a thiazide diuretic commonly used to treat hypertension and edema associated with congestive heart failure, hepatic cirrhosis, and renal disease in adults and pediatric patients. This policy promotes use of Step 1 formulations — generic hydrochlorothiazide tablets or capsules — prior to coverage of the Step 2 suspension formulation (Inzirqo). Approvals for a Step 2 product are provided for 1 year and coverage is contingent on meeting the step therapy criteria described in this policy.

OpenPayer